Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Multiple March Phase 3 wins (ralinepag ADVANCE OUTCOMES, positive TETON‑1 Tyvaso data) plus a just‑launched $2.0B buyback with a $1.5B ASR executed on 2026‑03‑09 and strong FY2025 revenue/FCF have driven a +16.9% 21‑day ROC and price ~10% above its 21‑day SMA; this combination of fresh clinical catalysts, aggressive capital return and strong technical momentum supports continued upside over the coming sessions.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • High Profitability • Ample Liquidity • Zero Debt UTHR combines exceptional profitability, strong free-cash-flow generation, and a debt-free, highly liquid balance sheet, though moderating EBITDA margins and elevated price-to-book warrant monitoring.
Price Behavior
Key Price Behavior Insights: • Lower trading levels • Support held • Rebound stalled Support Level: $488–$490 Resistance Level: $504–$507 UTHR remains in a short-term downtrend over the last month, with support at $488–$490 and upside requiring a break above $507, then $513–$516.
Sentiment & News
Key News Insights: • FDA Filing Acceptance • Phase III Enrollment • Accelerated Buyback United Therapeutics advanced key regulatory filings and late-stage programs while accelerating buybacks, offsetting recent share weakness with positive long-term catalysts.
AI Summary
UTHR is shifting from a high-margin PAH cash generator to a self-funded 2027–29 catalyst platform, with ralinepag and Tyvaso fibrosis decisions offering substantial upside but requiring patience as revenue softness and heavier reinvestment pressure margins; consider adding only on technical confirmation above $507–516, while a break below $488 would heighten near-term downside risk.
Description
United Therapeutics is a biopharmaceutical company that develops and markets therapies for chronic and life‑threatening conditions, with a primary emphasis on pulmonary hypertension and select oncology indications. Its commercial portfolio includes injectable, inhaled and oral prostacyclin‑based treatments for pulmonary arterial hypertension and an antibody therapy for high‑risk neuroblastoma, while its development pipeline comprises inhalation devices, a wearable drug pump, oral agents, gene therapy and ongoing clinical programs in related pulmonary disorders. The company maintains strategic collaborations for device and drug development and is based in Silver Spring, Maryland, where it was incorporated in 1996.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 31 | Apr 7 | UTHR | United Therapeutics Corporation | Multiple March Phase 3 wins (ralinepag ADVANCE OUTCOMES, positive TETON‑1 Tyvaso data) plus a just‑launched $2.0B buyback with a $1.5B ASR executed on 2026‑03‑09 and strong FY2025 revenue/FCF have driven a +16.9% 21‑day ROC and price ~10% above its 21‑day SMA; this combination of fresh clinical catalysts, aggressive capital return and strong technical momentum supports continued upside over the coming sessions. | Closed | -4.6% |
| Mar 13 | Mar 20 | UTHR | United Therapeutics Corporation | Strong near‑term setup: large capital return (up to $2B buyback and $1.5B ASR started 2026-03-09), two positive Phase 3 readouts in March (ralinepag ADVANCE OUTCOMES 2026-03-02 and nebulized Tyvaso TETON‑2 NEJM IPF data 2026-03-11), record FY2025 revenue and >40% net margin, plus ~+13.5% price move into mid‑March. Combination of active repurchases, de‑risked pipeline and technical breakout supports continued upside over the next few days, albeit with biotech volatility. | Closed | -2.2% |